314 related articles for article (PubMed ID: 29720980)
1. Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.
Kordaß T; Osen W; Eichmüller SB
Front Immunol; 2018; 9():813. PubMed ID: 29720980
[TBL] [Abstract][Full Text] [Related]
2. Novel microRNAs modulating ecto-5'-nucleotidase expression.
Kordaß T; Chao TY; Osen W; Eichmüller SB
Front Immunol; 2023; 14():1199374. PubMed ID: 37409119
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
[TBL] [Abstract][Full Text] [Related]
4. The TGF-β profibrotic cascade targets ecto-5'-nucleotidase gene in proximal tubule epithelial cells and is a traceable marker of progressive diabetic kidney disease.
Cappelli C; Tellez A; Jara C; Alarcón S; Torres A; Mendoza P; Podestá L; Flores C; Quezada C; Oyarzún C; San Martín R
Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165796. PubMed ID: 32289379
[TBL] [Abstract][Full Text] [Related]
5. Activity of ecto-5'-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes.
Bertoni APS; Bracco PA; de Campos RP; Lutz BS; Assis-Brasil BM; Meyer ELS; Saffi J; Braganhol E; Furlanetto TW; Wink MR
Mol Cell Endocrinol; 2019 Jan; 479():54-60. PubMed ID: 30184475
[TBL] [Abstract][Full Text] [Related]
6. Dys-regulation of peripheral transcript levels of ecto-5'-nucleotidase in multiple sclerosis patients.
Kobarfard F; Noroozi R; Beirami AD; Taheri M; Ghafouri-Fard S
Hum Antibodies; 2019; 27(3):161-165. PubMed ID: 30909201
[TBL] [Abstract][Full Text] [Related]
7. Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73).
Snider NT; Altshuler PJ; Wan S; Welling TH; Cavalcoli J; Omary MB
Mol Biol Cell; 2014 Dec; 25(25):4024-33. PubMed ID: 25298403
[TBL] [Abstract][Full Text] [Related]
8. CD73/NT5E is a Potential Biomarker for Cancer Prognosis and Immunotherapy for Multiple Types of Cancers.
Li H; Xie P; Li P; Du Y; Zhu J; Yuan Y; Wu C; Shi Y; Huang Z; Wang X; Liu D; Liu W
Adv Biol (Weinh); 2023 Feb; 7(2):e2200263. PubMed ID: 36480312
[TBL] [Abstract][Full Text] [Related]
9. Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73).
Minor M; Alcedo KP; Battaglia RA; Snider NT
Am J Physiol Cell Physiol; 2019 Dec; 317(6):C1079-C1092. PubMed ID: 31461341
[TBL] [Abstract][Full Text] [Related]
10. Juxta-articular joint-capsule mineralization in CD73 deficient mice: similarities to patients with NT5E mutations.
Li Q; Price TP; Sundberg JP; Uitto J
Cell Cycle; 2014; 13(16):2609-15. PubMed ID: 25486201
[TBL] [Abstract][Full Text] [Related]
11. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
Front Immunol; 2022; 13():975847. PubMed ID: 36091055
[TBL] [Abstract][Full Text] [Related]
12. Complex regulation of ecto-5'-nucleotidase/CD73 and A
Nedeljkovic N
Pharmacol Res; 2019 Jun; 144():99-115. PubMed ID: 30954629
[TBL] [Abstract][Full Text] [Related]
13. Ecto-5'-nucleotidase (CD73) inhibits nociception by hydrolyzing AMP to adenosine in nociceptive circuits.
Sowa NA; Taylor-Blake B; Zylka MJ
J Neurosci; 2010 Feb; 30(6):2235-44. PubMed ID: 20147550
[TBL] [Abstract][Full Text] [Related]
14. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.
Wang H; Lee S; Nigro CL; Lattanzio L; Merlano M; Monteverde M; Matin R; Purdie K; Mladkova N; Bergamaschi D; Harwood C; Syed N; Szlosarek P; Briasoulis E; McHugh A; Thompson A; Evans A; Leigh I; Fleming C; Inman GJ; Hatzimichael E; Proby C; Crook T
Br J Cancer; 2012 Apr; 106(8):1446-52. PubMed ID: 22454080
[TBL] [Abstract][Full Text] [Related]
15. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
[TBL] [Abstract][Full Text] [Related]
16. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
17. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
18. A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity.
Nevedomskaya E; Perryman R; Solanki S; Syed N; Mayboroda OA; Keun HC
J Proteome Res; 2016 Jan; 15(1):280-90. PubMed ID: 26629888
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Ecto-5'-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix.
Zhou P; Zhi X; Zhou T; Chen S; Li X; Wang L; Yin L; Shao Z; Ou Z
Cancer Biol Ther; 2007 Mar; 6(3):426-31. PubMed ID: 17471030
[TBL] [Abstract][Full Text] [Related]
20. CD73-adenosine: a next-generation target in immuno-oncology.
Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
